nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.04.2010 | Review

Combinatorial biomarker expression in breast cancer

verfasst von: Emad A. Rakha, Jorge S. Reis-Filho, Ian O. Ellis

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Current clinical management of breast cancer relies on the availability of robust clinicopathological variables and few well-defined biological markers. Recent microarray-based expression profiling studies have emphasised the importance of the molecular portraits of breast cancer and the possibility of classifying breast cancer into biologically and molecularly distinct groups. Subsequent large scale immunohistochemical studies have demonstrated that the added value of studying the molecular biomarker expression in combination rather than individually. Oestrogen (ER) and progesterone (PR) receptors and HER2 are currently used in routine pathological assessment of breast cancer. Additional biomarkers such as proliferation markers and ‘basal’ markers are likely to be included in the future. A better understanding of the prognostic and predictive value of combinatorial assessment of biomarker expression could lead to improved breast cancer management in routine clinical practice and would add to our knowledge concerning the variation in behaviour and response to therapy. Here, we review the evidence on the value of assessing biomarker expression in breast cancer individually and in combination and its relation to the recent molecular classification of breast cancer.

Geyer FC, Lopez-Garcia MA, Lambros MB, Reis-Filho JS (2009) Genetic characterisation of breast cancer and implications for clinical management. J Cell Mol Med (Published online September 14). doi:10.1111/j.1582-4934.2009.00906.x

Simpson PT, Reis-Filho JS, Gale T, Lakhani SR (2005) Molecular evolution of breast cancer. J Pathol 205:248–254PubMed

Alizadeh AA, Ross DT, Perou CM, van de Rijn M (2001) Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 195:41–52PubMed

Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930–942

Feng Y, Sun B, Li X, Zhang L, Niu Y, Xiao C et al (2006) Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res Treat 103(3):319–329PubMed

Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT (1994) The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 32:281–290PubMed

D’Eredita G, Giardina C, Martellotta M, Natale T, Ferrarese F (2001) Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 37:591–596PubMed

Pathology reporting of breast disease. A Joint Document Incorporating the Third Edition of the NHS Breast Screening Programme’s Guidelines for Pathology Reporting in Breast Cancer Screening and the Second Edition of The Royal College of Pathologists’ Minimum Dataset for Breast Cancer Histopathology. Sheffield, January 2005

Early Breast Cancer Trialists’ Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681–1692

10.

Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

11.

Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H et al (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18:1927–1934PubMed

12.

Weigelt B, Baehner FL, Reis-Filho JS (2010) The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 220:263–280PubMed

13.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMed

14.

van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536PubMed

15.

Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA et al (2006) The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24:4611–4619PubMed

16.

Osborne CK (1998) Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51:227–238PubMed

17.

Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh (1987) Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet 2:171–175

18.

Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467

19.

Robertson JF (1996) Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer 73:5–12PubMed

20.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMed

21.

Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393–10398PubMed

22.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMed

23.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423PubMed

24.

Anderson WF, Chatterjee N, Ershler WB, Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76:27–36PubMed

25.

Murphy LC, Watson P (2002) Steroid receptors in human breast tumorigenesis and breast cancer progression. Biomed Pharmacother 56:65–77PubMed

26.

Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6PubMed

27.

Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ et al (2006) Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 355:1851–1862PubMed

28.

Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K et al (2000) Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol 18:584–590PubMed

29.

Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C et al (2006) Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24:1656–1664PubMed

30.

Badve S, Nakshatri H (2009) Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol 62:6–12PubMed

31.

Esserman LJ, Ozanne EM, Dowsett M, Slingerland JM (2005) Tamoxifen may prevent both ER+ and ER− breast cancers and select for ER− carcinogenesis: an alternative hypothesis. Breast Cancer Res 7:R1153–R1158PubMed

32.

Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A’Hern R et al (2006) Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17:818–826PubMed

33.

Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J et al (2007) Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25:4772–4778PubMed

34.

Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D et al (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24:4660–4671PubMed

35.

Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL et al (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10:529–541PubMed

36.

Nikolsky Y, Sviridov E, Yao J, Dosymbekov D, Ustyansky V, Kaznacheev V et al (2008) Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res 68:9532–9540PubMed

37.

Natrajan R, Lambros MB, Rodriguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchio C et al (2009) Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 15:2711–2722PubMed

38.

Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS et al (2009) An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat. doi:10.1007/s10549-009-0501-3

39.

Horwitz KB, Koseki Y, McGuire WL (1978) Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103:1742–1751PubMed

40.

Horwitz KB, McGuire WL (1975) Specific progesterone receptors in human breast cancer. Steroids 25:497–505PubMed

41.

Lanari C, Lamb CA, Fabris VT, Helguero LA, Soldati R, Bottino MC et al (2009) The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 16:333–350PubMed

42.

Colomer R, Beltran M, Dorcas J, Cortes-Funes H, Hornedo J, Valentin V et al (2005) It is not time to stop progesterone receptor testing in breast cancer. J Clin Oncol 23:3868–3869 (author reply 3869–3870)PubMed

43.

Stendahl M, Ryden L, Nordenskjold B, Jonsson PE, Landberg G, Jirstrom K (2006) High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12:4614–4618PubMed

44.

Ryden L, Jonsson PE, Chebil G, Dufmats M, Ferno M, Jirstrom K et al (2005) Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 41:256–264PubMed

45.

Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP et al (1992) Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10:1284–1291PubMed

46.

Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J et al (2000) Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 89:111–117PubMed

47.

Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A et al (2006) Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98:1571–1581PubMed

48.

Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973–1979PubMed

49.

Hilsenbeck SG, Osborne CK (2006) Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res 12:1049s–1055sPubMed

50.

Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M (2005) Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23:7512–7517PubMed

51.

Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ et al (2004) Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol 22:1769–1770PubMed

52.

Allred DC (2008) Commentary: hormone receptor testing in breast cancer: a distress signal from Canada. Oncologist 13:1134–1136PubMed

53.

Ferno M, Stal O, Baldetorp B, Hatschek T, Kallstrom AC, Malmstrom P et al (2000) Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res Treat 59:69–76PubMed

54.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254–1261PubMedCrossRef

55.

Yu KD, Di GH, Wu J, Lu JS, Shen KW, Liu GY et al (2008) Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment. J Cancer Res Clin Oncol 134:1347–1354PubMed

56.

Bird PA, Hill AG, Houssami N (2008) Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol 15:1983–1988PubMed

57.

Rhodes A, Jasani B (2009) The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact? J Clin Pathol 62:95–96PubMed

58.

De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W et al (2008) Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? J Clin Oncol 26:335–336 (author reply 336–338)PubMed

59.

de Cremoux P, Tran-Perennou C, Elie C, Boudou E, Barbaroux C, Poupon MF et al (2002) Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction. Correlation with protein assays. Biochem Pharmacol 64:507–515PubMed

60.

Di Fronzo G, Coradini D, Cappelletti V, Miodini P, Granata G, Schwartz M et al (1990) Hormone receptors and disease-free survival in breast cancer: impact of increasing threshold levels. Anticancer Res 10:1699–1705PubMed

61.

Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P, Rasmussen BB et al (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol 25:3846–3852PubMed

62.

Rakha EA, Ellis IO (2008) Does estrogen receptor-negative/progesterone receptor-positive breast carcinoma exist? In reply. J Clin Oncol 26:335–340

63.

Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA (2001) Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol 19:18–27PubMed

64.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMed

65.

Kumar V, Abbas AK (2004) Fausto N: the breast, vol 3, 7th edn. Elsevier, Philadelphia, PA

66.

Goussard J, Genot JY (1994) What can be now expected of the determination of estrogen and progesterone receptors in the treatment of breast cancers. Bull Cancer 81:22–28PubMed

67.

Kinne DW, Butler JA, Kimmel M, Flehinger BJ, Menendez-Botet C, Schwartz M (1987) Estrogen receptor protein of breast cancer in patients with positive nodes. High recurrence rates in the postmenopausal estrogen receptor-negative groups. Arch Surg 122:1303–1306PubMed

68.

Parl FF, Schmidt BP, Dupont WD, Wagner RK (1984) Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 54:2237–2242PubMed

69.

Pichon MF, Broet P, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP et al (1996) Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 73:1545–1551PubMed

70.

Trendell-Smith NJ, Peston D, Shousha S (1999) Adenoid cystic carcinoma of the breast: a tumour commonly devoid of oestrogen receptors and related proteins. Histopathology 35:241–248PubMed

71.

Rosen PP, Cranor ML (1991) Secretory carcinoma of the breast. Arch Pathol Lab Med 115:141–144PubMed

72.

Weigelt B, Reis-Filho JS (2009) Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 6:718–730PubMed

73.

Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46:2884–2888PubMed

74.

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62PubMed

75.

Sundblad AS, Caprarulo L (1996) Immunohistochemical characteristics of mammary carcinomas with estrogen-negative and progesterone-positive receptors. Medicina (B Aires) 56:683–689

76.

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144PubMed

77.

Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B et al (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10:R65PubMed

78.

Desmedt C, Ruiz-Garcia E, Andre F (2008) Gene expression predictors in breast cancer: current status, limitations and perspectives. Eur J Cancer 44:2714–2720PubMed

79.

Bhargava R, Dabbs DJ (2008) Luminal B breast tumors are not HER2 positive. Breast Cancer Res 10:404 (author reply 405)PubMed

80.

Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168–1176PubMed

81.

Ihemelandu CU, Leffall LD, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH et al (2007) Molecular breast cancer subtypes in premenopausal african-american women, tumor biologic factors and clinical outcome. Ann Surg Oncol 14:2994–3003PubMedCrossRef

82.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750PubMed

83.

Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C et al (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25:1239–1246PubMed

84.

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMed

85.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145PubMed

86.

Yamauchi H, Stearns V, Hayes DF (2001) When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19:2334–2356PubMed

87.

Bartlett J, Mallon E, Cooke T (2003) The clinical evaluation of HER-2 status: which test to use? J Pathol 199:411–417PubMed

88.

Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM et al (2008) Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26:5697–5704PubMed

89.

Dandachi N, Dietze O, Hauser-Kronberger C (2002) Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 82:1007–1014PubMed

90.

Quenel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M et al (1995) The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 35:283–291PubMed

91.

Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE et al (2008) HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 14:7861–7870PubMed

92.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672PubMed

93.

Ward S, Pilgrim H, Hind D (2009) Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. Health Technol Assess 13(Suppl 1):1–6PubMed

94.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMed

95.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z et al (2003) Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95:142–153PubMedCrossRef

96.

Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808–3816PubMed

97.

Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell’Orto P, Del Curto B, Henriksen KL et al (2008) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1–98 randomised trial. Lancet Oncol 9:23–28PubMed

98.

Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O’Malley F, Dhesy-Thind B (2008) HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26:736–744PubMed

99.

Gianni L, Norton L, Wolmark N, Suter TM, Bonadonna G, Hortobagyi GN (2009) Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol 27:4798–4808PubMed

100.

Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A et al (2009) Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 27:3881–3886PubMed

101.

Pritchard KI, Shepherd LE, O’Malley FP, Andrulis IL, Tu D, Bramwell VH et al (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103–2111PubMed

102.

Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD et al (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253–1259PubMed

103.

Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC et al (1998) erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346–1360PubMed

104.

Konecny GE, Thomssen C, Luck HJ, Untch M, Wang HJ, Kuhn W et al (2004) Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 96:1141–1151PubMedCrossRef

105.

Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D et al (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496–1506PubMed

106.

Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF (2006) Molecular classification of breast cancer: limitations and potential. Oncologist 11:868–877PubMed

107.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM et al (2007) FOXA1 expression in breast cancer—correlation with luminal subtype A and survival. Clin Cancer Res 13:4415–4421PubMed

108.

Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu ZY et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374PubMed

109.

Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F (2005) p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 447:688–694PubMed

110.

Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15:2302–2310PubMed

111.

Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F et al (2007) The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 16:72–77

112.

Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, Ellis IO (2007) Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 50:434–438PubMed

113.

Marchiò C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, Lord CJ, Hungermann D, Fenwick K, Tamber N, Mackay A, Palacios J, Sapino A, Buerger H, Ashworth A, Reis-Filho JS (2008) The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 216:399–407PubMed

114.

Pinto AE, Andre S, Pereira T, Nobrega S, Soares J (2001) C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol 12:525–533PubMed

115.

Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685PubMed

116.

Prat A, Baselga J (2008) The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 5:531–542PubMed

117.

Darb-Esfahani S, Loibl S, Muller BM, Roller M, Denkert C, Komor M et al (2009) Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 11:R69PubMed

118.

Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059–1065PubMed

119.

Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26:2568–2581PubMed

120.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334PubMed

121.

Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS et al (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69:4116–4124PubMed

122.

Howell A, Bundred NJ, Cuzick J, Allred DC, Clarke R (2008) Response and resistance to the endocrine prevention of breast cancer. Adv Exp Med Biol 617:201–211PubMed

123.

Conte P, Guarneri V, Bengala C (2007) Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. Clin Breast Cancer 7:841–849PubMed

124.

Bachleitner-Hofmann T, Pichler-Gebhard B, Rudas M, Gnant M, Taucher S, Kandioler D et al (2002) Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen. Clin Cancer Res 8:3427–3432PubMed

125.

Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC et al (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23:2469–2476PubMed

126.

Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM (2005) Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 11:4835–4842PubMed

127.

Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10:331S–336SPubMed

128.

Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E et al (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85–95PubMed

129.

Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM et al (2003) The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144:5105–5117PubMed

130.

Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D et al (2005) Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer 12(Suppl 1):S29–S36PubMed

131.

Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M et al (2008) Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13:91–104PubMed

132.

Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092PubMed

133.

Dixon MJ (2008) Role of ErbB2 in selection for adjuvant tamoxifen or aromatase inhibitors. Womens Health (Lond Engl) 4:229–231

134.

Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ et al (2009) NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw 7(Suppl 6):S1–S21PubMed

135.

Dairkee SH, Mayall BH, Smith H, Hackett A (1987) Monoclonal marker that predicts early recurrence of breast cancer. Lancet 1:514PubMed

136.

Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG et al (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208:495–506PubMed

137.

Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF et al (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42:3149–3156PubMed

138.

van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J et al (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161:1991–1996PubMed

139.

Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S et al (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11:5175–5180PubMed

140.

Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA (2009) Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. Cancer 115:4917–4923PubMed

141.

Foulkes WD, Grainge MJ, Rakha EA, Green AR, Ellis IO (2009) Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat 117:199–204PubMed

142.

Gusterson B (2009) Do ‘basal-like’ breast cancers really exist? Nat Rev Cancer 9:128–134PubMed

143.

Rakha E, Reis-Filho JS (2009) Basal-like breast carcinoma: from expression profiling to routine practice. Arch Pathol Lab Med 133:860–868PubMed

144.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376PubMed

145.

Rakha EA, Tan DS, Foulkes WD, Ellis IO, Tutt A, Nielsen TO et al (2007) Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res 9:404 (author reply 405)PubMed

146.

Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D et al (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13:1198–1207PubMed

147.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1–22PubMed

148.

Bergh J, Jonsson PE, Glimelius B, Nygren P (2001) A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 40:253–281PubMed

149.

Pusztai L, Hortobagyi GN (1998) High-dose chemotherapy: how resistant is breast cancer? Drug Resist Updat 1:62–72PubMed

150.

Arpino G, Ciocca DR, Weiss H, Allred DC, Daguerre P, Vargas-Roig L et al (2005) Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 92:69–75PubMed

151.

Yamashiro H, Toi M (2008) Update of evidence in chemotherapy for breast cancer. Int J Clin Oncol 13:3–7PubMed

152.

van Diest PJ, van der Wall E, Baak JPA (2004) Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 57:675–681PubMed

153.

Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P (1993) Proliferation index as a prognostic marker in breast cancer. Cancer 71:3926–3931PubMed

154.

Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ (2005) Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 16:1723–1739PubMed

155.

Vincent-Salomon A, Rousseau A, Jouve M, Beuzeboc P, Sigal-Zafrani B, Freneaux P et al (2004) Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer 40:1502–1508PubMed

156.

Miglietta L, Vanella P, Canobbio L, Parodi MA, Guglielmini P, Boccardo F (2009) Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index. Anticancer Res 29:1621–1625PubMed

157.

Aleskandarany MA, Green AR, Rakha EA, Mohammed RA, Elsheikh SE, Powe DG et al. (2009) Growth fraction as a predictor of response to chemotherapy in node negative breast cancer. Int J Cancer. doi:10.1002/ijc.24860

158.

Ellis MJ, Tao Y, Luo J, A’Hern R, Evans DB, Bhatnagar AS et al (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380–1388PubMed

159.

Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M et al (2008) Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100:207–212PubMed

160.

Jacquemier J, Charafe-Jauffret E, Monville F, Esterni B, Extra JM, Houvenaghel G et al (2009) Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res 11:R23PubMed

161.

Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MC et al (2006) Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 24:3039–3047PubMed

162.

Cuzick J, Dowsett M, Wale C, Salter J, Quinn E, Zabaglo L et al (2009) Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score—results from TransATAC. San Antonio Breast Cancer Symposium, December 2009, Abstract No (74)

163.

Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M (2009) Triple negative breast cancer—current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 153:13–17PubMed

164.

Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J et al (2006) Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 12:2468–2475PubMed

165.

Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC et al (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200–206PubMed

166.

Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R et al (2008) Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 88:491–503PubMed

167.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W et al (2007) Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer 7:63PubMed

168.

Ogston KN, Miller ID, Schofield AC, Spyrantis A, Pavlidou E, Sarkar TK et al (2004) Can patients’ likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment? Breast Cancer Res Treat 86:181–189PubMed

169.

Mauri FA, Maisonneuve P, Caffo O, Veronese S, Aldovini D, Ferrero S et al (1999) Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2 and PgR expression: an immunohistochemical study on breast carcinoma with long-term follow-up. Int J Oncol 15:1137–1147PubMed

170.

Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S et al (2004) Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6:R24–R30PubMed

171.

Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671–679PubMed

172.

Lancashire LJ, Powe DG, Reis-Filho JS, Rakha E, Lemetre C, Weigelt B et al (2010) A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. Breast Cancer Res Treat 120:83–93PubMed

173.

Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800PubMed

174.

Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M et al (2006) A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8:R25PubMed

175.

Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB et al (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560–569PubMed

176.

Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J et al (2005) Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 11:3315–3319PubMed

177.

Chang JC, Makris A, Gutierrez MC, Hilsenbeck SG, Hackett JR, Jeong J et al (2008) Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat 108:233–240PubMed

178.

van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMed

179.

Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183–1192PubMedCrossRef

180.

Espinosa E, Vara JA, Redondo A, Sanchez JJ, Hardisson D, Zamora P et al (2005) Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study. J Clin Oncol 23:7278–7285PubMed

181.

Dunkler D, Michiels S, Schemper M (2007) Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer 43:745–751PubMed

Titel: Combinatorial biomarker expression in breast cancer
verfasst von: Emad A. Rakha
Jorge S. Reis-Filho
Ian O. Ellis
Publikationsdatum: 01.04.2010
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0746-x

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Combinatorial biomarker expression in breast cancer

Abstract

Neu im Fachgebiet Onkologie

Blutdrucksenkung könnte Uterusmyome verhindern

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

DNA methylation of polycomb group target genes in cores taken from breast cancer centre and periphery

SOX9 mediates the retinoic acid-induced HES-1 gene expression in human breast cancer cells

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

The substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells

Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma

Neu im Fachgebiet Onkologie

Blutdrucksenkung könnte Uterusmyome verhindern

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Update Onkologie